GLAND PHARMA LIMITED reported revenue of ₹1,800 cr and net profit of ₹317 cr in Q1 FY27 (quarter ended 30 Jun 2026), +47.1% year on year. Below is the full quarter-wise results table with revenue, operating profit, margins, tax, EPS and annual history — updated automatically from exchange filings.
GLAND PHARMA LIMITED (GLAND) has reported its Q1 FY27 results for the quarter ended 2026-06-30. The company posted revenue of ₹1,800 cr and a net profit of ₹317 cr, translating into earnings per share of ₹19.23.
Compared with the same quarter a year earlier, revenue grew by +19.6% and net profit grew strongly by +47.1%. Profit rising faster than revenue points to better cost control or operating leverage flowing through the P&L.
Operating profit for the quarter stood at ₹378 cr, an operating margin of 21.0% versus 17.7% a year ago — a gain of 3.3 percentage points.
GLAND quarter-wise results table
Revenue
₹1,800 cr
+19.6%YoY
Net profit
₹317 cr
+47.1%YoY
Operating profit
₹378 cr
+41.8%YoY
EPS
₹19.23
+47.0%YoY
GLAND PHARMA LIMITED (GLAND) quarter-wise results — revenue, operating profit, net profit, margins, EPS and growth
Quarter
Revenue
Operating profit
Net profit
OPM
Net margin
EPS
Profit YoY
Profit QoQ
Q1 FY272026-06-30
₹1,800 cr
₹378 cr
₹317 cr
21.0%
17.6%
₹19.23
+47.1%
-13.6%
Q4 FY262026-03-31
₹1,743 cr
₹404 cr
₹367 cr
23.2%
21.0%
₹22.26
+96.6%
+40.2%
Q3 FY262025-12-31
₹1,695 cr
₹327 cr
₹261 cr
19.3%
15.4%
₹15.87
—
+21.3%
Q1 FY262025-06-30
₹1,506 cr
₹267 cr
₹215 cr
17.7%
14.3%
₹13.08
—
+15.5%
Q4 FY252025-03-31
₹1,425 cr
₹252 cr
₹187 cr
17.7%
13.1%
₹11.32
—
—
TTM (last 4 quarters)
₹6,744 cr
₹1,376 cr
₹1,161 cr
20.4%
17.2%
₹70.44
—
—
Consolidated figures as reported to the exchanges, shown in ₹ crore. OPM = operating profit margin. Updated automatically whenever a new quarter is filed.
GLAND quarterly income statement
Line-item results for the last six quarters as filed — sales, expenses, operating profit, interest, tax and profit after tax in ₹ crore.
GLAND PHARMA LIMITED quarterly income statement
Particulars
Q1 FY272026-06-30
Q4 FY262026-03-31
Q3 FY262025-12-31
Q1 FY262025-06-30
Q4 FY252025-03-31
Revenue / Sales
₹1,800 cr
₹1,743 cr
₹1,695 cr
₹1,506 cr
₹1,425 cr
Total expenses
₹1,422 cr
₹1,338 cr
₹1,368 cr
₹1,239 cr
₹1,173 cr
Gross profit
₹1,176 cr
₹1,151 cr
₹1,119 cr
₹984 cr
₹937 cr
Operating profit (EBIT)
₹378 cr
₹404 cr
₹327 cr
₹267 cr
₹252 cr
Operating margin
21.0%
23.2%
19.3%
17.7%
17.7%
Interest cost
₹4.36 cr
₹10.03 cr
₹3.93 cr
₹11.5 cr
₹7.45 cr
Profit before tax
₹435 cr
₹506 cr
₹362 cr
₹313 cr
₹288 cr
Tax expense
₹118 cr
₹139 cr
₹101 cr
₹97.26 cr
₹102 cr
Effective tax rate
27.1%
27.5%
27.8%
31.1%
35.3%
Net profit (PAT)
₹317 cr
₹367 cr
₹261 cr
₹215 cr
₹187 cr
Net profit margin
17.6%
21.0%
15.4%
14.3%
13.1%
Basic EPS
₹19.23
₹22.26
₹15.87
₹13.08
₹11.32
Diluted EPS
₹19.22
₹22.23
₹15.87
₹13.08
₹11.32
GLAND results growth — YoY and QoQ
Quarterly growth rates, year on year and quarter on quarter
Growth
Q1 FY27
Q4 FY26
Q3 FY26
Q1 FY26
Q4 FY25
Revenue YoY
+19.6%
+22.3%
—
—
—
Revenue QoQ
+3.3%
+2.8%
+12.6%
+5.7%
—
Operating profit YoY
+41.8%
+60.6%
—
—
—
Operating profit QoQ
-6.5%
+23.6%
+22.7%
+5.9%
—
Net profit YoY
+47.1%
+96.6%
—
—
—
Net profit QoQ
-13.6%
+40.2%
+21.3%
+15.5%
—
EPS YoY
+47.0%
+96.6%
—
—
—
EPS QoQ
-13.6%
+40.3%
+21.3%
+15.5%
—
GLAND annual results history
Full-year performance for GLAND PHARMA LIMITED, useful for reading each quarter in context.
GLAND PHARMA LIMITED annual income statement
Particulars
FY262026-03-31
FY252025-03-31
FY242024-03-31
FY232023-03-31
Revenue / Sales
₹6,403 cr
₹5,584 cr
₹5,642 cr
₹3,592 cr
Total expenses
₹5,196 cr
₹4,694 cr
₹4,646 cr
₹2,722 cr
Gross profit
₹4,160 cr
₹3,493 cr
₹3,469 cr
₹1,906 cr
Operating profit (EBIT)
₹1,207 cr
₹890 cr
₹996 cr
₹870 cr
Operating margin
18.8%
15.9%
17.7%
24.2%
Interest cost
₹29.56 cr
₹37.4 cr
₹21.79 cr
₹6.29 cr
Profit before tax
₹1,465 cr
₹1,063 cr
₹1,133 cr
₹1,055 cr
Tax expense
₹437 cr
₹364 cr
₹360 cr
₹274 cr
Effective tax rate
29.9%
34.3%
31.8%
25.9%
Net profit (PAT)
₹1,027 cr
₹699 cr
₹772 cr
₹781 cr
Net profit margin
16.0%
12.5%
13.7%
21.7%
Basic EPS
₹62.35
₹42.40
₹46.90
₹47.44
Diluted EPS
₹62.28
₹42.40
₹46.89
₹47.43
Revenue trend and demand read-through
Topline for Q1 FY27 came in at ₹1,800 cr against ₹1,506 cr in Q1 FY26, and ₹1,743 cr in the preceding Q4 FY26 quarter.
On a sequential basis revenue grew +3.3%. Sequential moves are the quickest read on demand momentum because they strip out the base effect of a year-old quarter, though seasonality can distort a single quarter.
Total expenses for the quarter were ₹1,422 cr, or 79.0% of revenue, with operating profit grew +41.8% year on year.
Margins, tax and profitability
Net profit of ₹317 cr works out to a net margin of 17.6% compared with 14.3% in the year-ago quarter. Margin expansion of this kind usually reflects a better product or service mix, softer input costs, or tighter overheads.
Below the operating line, GLAND PHARMA LIMITED reported profit before tax of ₹435 cr, a tax charge of ₹118 cr (effective rate 27.1%), interest cost of ₹4.36 cr. Reading these together with operating profit shows how much of the quarter's earnings were driven by the core business versus financing and tax movements.
Sequentially, net profit moved from ₹367 cr in Q4 FY26 to ₹317 cr in Q1 FY27, a change of -13.6%.
Trailing twelve months and annual context
Across the trailing four quarters GLAND PHARMA LIMITED has generated revenue of ₹6,744 cr and net profit of ₹1,161 cr, a trailing net margin of 17.2%. The trailing view smooths out one-off quarters and is the number most valuation multiples are built on.
On a full-year basis, FY26 revenue was ₹6,403 cr with net profit of ₹1,027 cr and EPS of ₹62.35, versus the prior year where revenue grew +14.7% and profit grew +47.1%.
What to watch in the next GLAND quarter
For the coming quarters the numbers worth tracking on this page are revenue momentum, the operating margin trend, the interest burden and whether EPS keeps pace with profit growth. A sustained run of year-on-year profit growth is what usually drives a re-rating rather than any single quarter.
GLAND PHARMA LIMITED has not yet intimated its next results date to the exchange. This page refreshes automatically from filings and the board-meeting calendar, so the tables above will reflect the next quarter as soon as it is reported.
All figures here are as reported to the exchanges and shown in ₹ crore, without adjustment. This is information and analysis, not investment advice.
GLAND results coverage
No results report published for GLAND yet — our desk covers each quarter within minutes of the filing.
What were GLAND PHARMA LIMITED (GLAND) Q1 FY27 results?
In Q1 FY27 (quarter ended 30 Jun 2026), GLAND PHARMA LIMITED reported revenue of ₹1,800 cr and net profit of ₹317 cr, a change of +47.1% year on year on +19.6% revenue growth. EPS stood at ₹19.23.
What is GLAND profit margin in Q1 FY27?
GLAND PHARMA LIMITED posted a net profit margin of 17.6% and an operating margin of 21.0% in Q1 FY27. On a trailing twelve-month basis, revenue is ₹6,744 cr and net profit ₹1,161 cr.
Did GLAND results beat the previous quarter?
GLAND PHARMA LIMITED net profit changed -13.6% quarter on quarter, from ₹367 cr in Q4 FY26 to ₹317 cr in Q1 FY27.
When are GLAND PHARMA LIMITED (GLAND) quarterly results?
GLAND PHARMA LIMITED has not yet intimated its next results date to the exchange. This page updates automatically from the exchange board-meeting calendar.
Where can I see GLAND latest quarterly results?
Results coverage for GLAND will appear here as soon as the company reports. Meanwhile you can track live price and technicals on the GLAND stock page.
What is GLAND PHARMA LIMITED annual revenue and profit?
For FY26, GLAND PHARMA LIMITED reported full-year revenue of ₹6,403 cr and net profit of ₹1,027 cr, with EPS of ₹62.35.
How many quarterly results has GLAND declared recently?
Past results dates for GLAND will be listed here from the exchange calendar.
Results dates sourced from the exchange board-meeting calendar; reported figures from company filings, last refreshed 10 Sept 2026. For information only, not investment advice.
